₹10.10
(Market cap
₹3,959 Cr
Recently Viewed
Clear AllMarket cap
₹3,959 Cr
Revenue (TTM)
₹897 Cr
P/E Ratio
44.2
P/B Ratio
5.3
Div. Yield
0.1 %
Value Research Rating
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹90 Cr
ROE
11.9 %
ROCE
12.6 %
Industry P/E
45.59
EV/EBITDA
23.3
Debt to Equity
0.5
Book Value
₹80.4
EPS
₹9.8
Face value
1
Shares outstanding
93,652,030
CFO
₹545.78 Cr
EBITDA
₹973.89 Cr
Net Profit
₹441.18 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
SMS Pharma
| 37.0 | 10.8 | 25.4 | 113.1 | 86.0 | 23.6 | 20.9 |
|
BSE Healthcare
| -1.8 | -1.7 | -2.4 | 7.8 | 24.3 | 13.4 | 10.9 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
SMS Pharma
| 20.9 | 99.3 | 43.4 | -35.6 | 8.2 | 183.7 | -41.0 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
SMS Pharma
|
425.1 | 3,959.1 | 897.1 | 87.1 | 14.9 | 13.1 | 44.2 | 5.3 |
| 2,391.9 | 19,329.0 | 1,215.1 | 284.8 | 28.7 | 21.1 | 67.4 | 12.7 | |
| 727.3 | 14,330.4 | 7,266.8 | 627.5 | 11.9 | 12.6 | 22.8 | 2.6 | |
| 637.0 | 15,872.6 | 5,092.5 | 545.5 | 15.9 | 14.1 | 29.1 | 3.6 | |
| 890.8 | 14,129.0 | 7,918.4 | 429.9 | 10.7 | 7.2 | 32.7 | 2.1 | |
| 1,105.9 | 19,934.9 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 12.8 | 2.3 | |
| 1,362.7 | 15,930.1 | 1,419.3 | 20.1 | 8.4 | 0.5 | 792.5 | 2.7 | |
| 146.8 | 19,340.6 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.4 | |
| 406.2 | 16,266.7 | 3,720.2 | 352.1 | 13.7 | 8.2 | 46.2 | 3.4 | |
| 1,355.0 | 22,107.1 | 3,151.0 | -10.0 | 8.4 | 2.5 | 1004.9 | 4.8 |
No Review & Analysis are available.
SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers anti-ulcer, anti-fungal, anti-migraine, anti-diabetic, anti-epileptic, anti-psychotic, anti-inflammatory,... anti-fungal, anti-viral, anti-coagulant, and anti-retroviral products. It is also involved in the contract research activities. The company also exports its products. SMS Pharmaceuticals Limited was incorporated in 1987 and is based in Hyderabad, India. Read more
Incorporated
1987
Chairman
Ramesh Babu Potluri
Managing Director
Ramesh Babu Potluri
Headquarters
Hyderabad, Telangana
Website
Looking for more details about SMS Pharmaceuticals Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of SMS Pharmaceuticals Ltd is ₹425.10 (NSE) and ₹425.75 (BSE) as of 10-Apr-2026 13:29 IST. SMS Pharmaceuticals Ltd has given a return of 86.01% in the last 3 years.
The P/E ratio of SMS Pharmaceuticals Ltd is 44.19 times as on 10-Apr-2026, a 3 discount to its peers’ median range of 45.59 times.
The P/B ratio of SMS Pharmaceuticals Ltd is 5.26 times as on 10-Apr-2026, a 65 premium to its peers’ median range of 3.19 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
27.27
|
3.02
|
|
2024
|
30.25
|
2.97
|
|
2023
|
0.00
|
1.06
|
|
2022
|
12.76
|
1.69
|
|
2021
|
16.84
|
2.57
|
The 52-week high and low of SMS Pharmaceuticals Ltd are Rs 433.90 and Rs 201.71 as of 10-Apr-2026.
SMS Pharmaceuticals Ltd has a market capitalisation of ₹ 3,959 Cr as on 10-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in SMS Pharmaceuticals Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.